Skip to main content
Premium Trial:

Request an Annual Quote

Appeals Court Affirms Stratagene Victory in Invitrogen Patent Suit

NEW YORK, Feb. 28 - A federal appeals court has handed Stratagene a victory in an ongoing patent dispute sparked by Invitrogen, Stratagene said on Thursday.

The court's judgment, which affirms an earlier decision by a Maryland District Court, allows Stratagene to continue marketing its RNase H minus reverse transcriptase enzyme.
According to Stratagene, Invitrogen filed suit against it on June 29, 2000, saying that its StrataScript RT RNase product infringed on Invitrogen's patent No. 6,063,608.


Then, on Feb. 13 last year, Invitrogen asked the Maryland court to order Stratagene to remove the StrataScript product from the market. Fourth months later, the court denied the request. 

"The appellate Court's decision ensures Stratagene's ability to continue its rightful place in the RT market," the company said in a brief statement.

Oral arguments before the Federal Circuit were held on Feb. 8, according to Stratagene. 


Invitrogen officials were not immediately available for comment.


The victory for La Jolla, Calif.-based Stratagene is the second one of its kind in as many months. In a final judgment handed down on Jan. 31, the US District Court for the Western District of Texas said that Stratagene did not infringe on Invitrogen patents related to its competent cell products.


According to Stratagene, the dispute began when Invitrogen sued Stratagene for allegedly infringing one of its patents, No. 4,981,797. Then, in August last year, Invitrogen voluntarily withdrew its allegations, made against Stratagene's electrocompetent cell and certain chemically competent cell products, Stratagene said.


Invitrogen's position further eroded that month when the court narrowed its interpretation of the '797 patent, Stratagene said. Following the court's recent decision, Invitrogen withdrew its remaining patent-infringement allegations.


"We still feel strongly that our patent holds ... and we decided to continue to fight in appeals court," Mary Cassoni, an Invitrogen spokesperson, said in early February in response to the '797 patent suit.


"This particular lawsuit doesn't have a lot of risk for us," said Cassoni. "If we lost, we wouldn't be collecting royalties from Stratagene that we believe we're due. This still doesn't affect our business."


Invitrogen has foreign patents connected with the competent cell technology that is may use to persue additional litigation, added Cassoni. 


Competent cells, at the heart of the dispute, contain cell walls that have been manipulated to let them absorb various DNA in order to facilitate cloning projects. Stratagene creates various types of competent cell strains.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.